Shares of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) have been given a consensus rating of “Hold” by the twelve research firms that are currently covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $52.63.

ZLTQ has been the topic of several research reports. Aegis reissued a “hold” rating and set a $56.00 price target on shares of Zeltiq Aesthetics in a research report on Monday, April 24th. Canaccord Genuity reissued a “hold” rating and set a $56.50 price target on shares of Zeltiq Aesthetics in a research report on Friday, March 10th. Finally, Zacks Investment Research raised shares of Zeltiq Aesthetics from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a research report on Wednesday, March 29th.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/03/zeltiq-aesthetics-inc-nasdaqzltq-given-consensus-recommendation-of-hold-by-brokerages.html.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 56.48 on Monday. Zeltiq Aesthetics has a 12-month low of $23.58 and a 12-month high of $56.50. The stock has a 50 day moving average of $56.05 and a 200 day moving average of $46.95.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of Zeltiq Aesthetics by 136,866.2% in the first quarter. BlackRock Inc. now owns 4,407,573 shares of the medical equipment provider’s stock valued at $245,106,000 after buying an additional 4,404,355 shares during the period. Vanguard Group Inc. boosted its stake in shares of Zeltiq Aesthetics by 35.8% in the first quarter. Vanguard Group Inc. now owns 3,239,176 shares of the medical equipment provider’s stock valued at $180,130,000 after buying an additional 854,506 shares during the period. Palo Alto Investors LLC boosted its stake in shares of Zeltiq Aesthetics by 18.1% in the first quarter. Palo Alto Investors LLC now owns 2,032,692 shares of the medical equipment provider’s stock valued at $113,038,000 after buying an additional 311,929 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Zeltiq Aesthetics by 1,253.4% in the first quarter. JPMorgan Chase & Co. now owns 1,308,217 shares of the medical equipment provider’s stock valued at $72,749,000 after buying an additional 1,211,553 shares during the period. Finally, State Street Corp boosted its stake in shares of Zeltiq Aesthetics by 9.3% in the first quarter. State Street Corp now owns 868,262 shares of the medical equipment provider’s stock valued at $48,283,000 after buying an additional 74,212 shares during the period.

About Zeltiq Aesthetics

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians.

Analyst Recommendations for Zeltiq Aesthetics (NASDAQ:ZLTQ)

Receive News & Ratings for Zeltiq Aesthetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.